Search results
Results from the WOW.Com Content Network
(Reuters) -Shares of Grail fell as much as 13.7% in their market debut on Tuesday after being spun out of gene-sequencing company Illumina. The stock traded as low as $15.84 after opening at $18. ...
The blood test, called Galleri, can detect multiple types of cancer early and targets 80% of cancers currently not screened for that result in cancer deaths, Grail CEO Bob Ragu
Meanwhile, after researching the issue of Illumina’s controversial acquisition of Grail, I think that there’s an 80%-90% chance that the deal will be approved. Illumina Stock Will Be ...
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms. [ 3 ]
Grail uses Illumina sequencing technology for tests. [26] Grail planned to roll out the tests by 2019. [27] In September 2020, Illumina announced a proposed cash and stock deal to acquire Grail for $8 billion. [28] [29] In November 2018, Illumina proposed the acquisition of Pacific Biosciences for $8.00 per share or around $1.2 billion in total.
Stock name Symbol Country of origin A. O. Smith Corporation: AOS: US A10 Networks, Inc. ATEN: US AAC Holdings Inc. AAC: US AAR Corporation: AIR: US Aaron's Inc.
The stock was down -8.49% to trade at $857.81 per share in the afternoon session as of 1:16 p.m. ET. 12:54 p.m. ET: Stocks lose steam after strong morning gains Here were the main moves in markets ...
Here's what else happened today: Disney said it will appoint Bob Iger's successor as CEO by early 2026. Goldman Sachs said investors should prepare for a decade of muted returns in the stock market.